US scientists have achieved enormous success in editing the immune systems of three cancer patients using CRISPR technology. The surprise is that they do it without getting any adverse effects on the patient’s body. Most of the medicines provide the best treatment, but show some side effects. But, it is good news that CRISPER shows no side effects. It was almost an impossible task to edit the immune system from earlier biotechnology, but from now, it revoluted the biomedical research.
The result of the first phase clinical trial of CRISPER has now published the journal Science.
Still, they are not sure whether CRISPER is safe for treating cancer or not. CRISPER is not successful in saving the life of one patient as he was in the last of cancer. Still, it was successful in improving the immunogenicity of the other two cancer patients. They don’t show any toxicity on this patient.
At the University of Pennsylvania (UPenn), the researches are done by removing the T-cells from the patient’s blood and used in CRISPR to delete the genes from those cells. Doing this will make some changes in the gene and develop the immune system efficiency to fight against cancer.
In this technology, they use a Virus to maintain the framework of T-cells for attacking the particular type of protein present in the cancer cells. These cancer cells are known as NY-ESO-1. Organized NY-ESO-1 is injected into the protein sequence and infused inside the cells of the patients.
The principal investigator of the study of CRISPER cells, Edward Stadtmauer, says that in cancer patient CRISPER technology is successful for changing the immune system of the patient to identify the defect of cancer-causing protein. The inadequate protein is responsible for creating disease by making the cell division process more rapid. CRISPER can quickly correct this sequence and change the cell to healthy cells. Changing it to normal, one can fix the codon sequence, and thus, treat cancer in the upcoming babies. CRISPER also has an additional characteristic of not only correct the protein sequence but also making it more advance for protection against another disease. He also says that this method of biotechnology will be successful in 99% of the patient because this technique works on the genetic level.
The treatment in the genetic level starts by combining the patient T-cells with the patient DNA sequence to identify the defect. For cutting and joining the protein fragments, different endonuclease or DNA Gyrase enzymes are useful.
This biotechnology is not yet 100% sure to implement for all clinical practice. Research has been going to improve the accuracy of treatment. If this technology is successful, then most of the disease can be cured very easily. As it works on the genetic level, thus, most of the organ defects can be easily remedied. Even CRISPER technology has full applications not only in the clinical field. It also deals with finding the health report of Aeronautics just by taking the cell samples.